Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 17;11:616101. doi: 10.3389/fphar.2020.616101

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Zhao, Li, Wu, Wang, Ma and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Tumor growth and angiogenesis is conspicuously restrained by exosome therapy. (A) Scheme of experimental design. DMBA injection induced tumor production within 4 weeks, and exosomes were injected every 3–4 days for a total of four injections. (B and C) Tumor growth and volume of the control and exosomes groups after four injections of exosomes. ▲ indicates days of exosome treatment. (D) H&E sections of tumor tissues in the control and exosome treatment group on day 25. (E) Histological sections of tumors stained with Hoechst (blue), Dextran-FITC (green), and VE Cadherin (red) at day 25. Reproduced from (Rosenberger et al., 2019) with permission from Scientific Reports. DAPI, 4′,6-diamidino-2-phenylindole; DMBA, 7,12-dimethylbenzanthracene; FITC, fluorescein; isothiocyanate; H&E, hematoxylin-eosin; VE, vascular endothelial.